Hetero Research Foundation

Other

Hetero Drugs Limited

Thungathurthy Srinivasa Rao

Bandi Parthasaradhi Reddy

Kura Rathnakar Reddy

Dasari Muralidhara Reddy

Bandi Vamsi Krishna

Rapolu Raji Reddy

Kura Rathnakarreddy

The present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine.

Process for fosaprepitant

The present invention provides processes for the preparation of i) Regorafenib (4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, BAY 73-4506, Stivarga&#xae;) and its pharmaceutically acceptable salt thereof; ii) a crystalline solid of Regorafenib tosylate; iii) Regorafenib Polymorph I from Regorafenib tosylate, and iv) a pure 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide from 4-amino-3-fluorophenol and 4-chloro-N-methylpicolinamide in the presence of potassium tert-butoxide.

Process for Regorafenib

The present invention provides a novel process for the preparation of sorafenib tosylate polymorph III.

Process for sorafenib tosylate polymorph III

The present invention provides a commercially viable process for preparing pazopanib and its pharmaceutically acceptable acid addition salts thereof in high yields using novel intermediate. The present invention also provides a process for the purification of pazopanib hydrochloride.

Process for the preparation of pazopanib using novel intermediate

The present invention provides a novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical compositions comprising it.

Polymorph of nilotinib hydrochloride

The present invention provides an improved and commercially viable process for preparation of erlotinib substantially free of N-methoxyethyl impurity, namely N-[(3-ethynylphenyl)-(2-methoxyethyl)]-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, and its pharmaceutically acceptable acid addition salts thereof in high purity and in high yield. According to the present invention, erlotinib or a pharmaceutically acceptable acid addition salt of erlotinib substantially free of N-methoxyethyl impurity is prepared by isolating erlotinib or a pharmaceutically acceptable salt of erlotinib from a solvent medium comprising dimethyl sulfoxide and an alcoholic solvent.

Process for erlotinib hydrochloride

The present invention provides a novel crystalline form of sunitinib malate, process for its preparation and to pharmaceutical composition containing it. The present invention also provides a process for preparation of sunitinib malate crystal form I. Thus, for example, sunitinib malate was added to water, the mixture was heated to 80 deg C. to obtain a clear solution and stirred for 30 minutes at 80 deg C., slowly cooled to room temperature and the solution was subjected to freeze drying at about &#x2212;90 deg C. for 8 hours to give sunitinib malate crystalline form III.

Growing community of inventors

Hyderabad Telangana, India

Thungathurthy Srinivasa Rao